Edition:
India

MorphoSys AG (MORG.DE)

MORG.DE on Xetra

104.80EUR
22 Nov 2019
Change (% chg)

€0.80 (+0.77%)
Prev Close
€104.00
Open
€104.00
Day's High
€105.90
Day's Low
€103.40
Volume
123,037
Avg. Vol
149,670
52-wk High
€114.70
52-wk Low
€79.70

Latest Key Developments (Source: Significant Developments)

Morphosys Says Co's CSO Markus Enzelberger Has Decided To Step Down
Thursday, 21 Nov 2019 

Nov 20 (Reuters) - MorphoSys AG ::MORPHOSYS SAYS MARKUS ENZELBERGER, CO'S CHIEF SCIENTIFIC OFFICER HAS DECIDED TO STEP DOWN AS CSO AND MEMBER OF COMPANY'S MANAGEMENT BOARD.MARKUS ENZELBERGER WILL LEAVE MORPHOSYS ON FEBRUARY 29, 2020.MORPHOSYS- FOLLOWING ENZELBERGER'S DEPARTURE, CO'S RESEARCH ORGANIZATION WILL BE INTEGRATED INTO CLINICAL DEVELOPMENT SEGMENT UNDER MALTE PETERS.  Full Article

Morphosys AG Reports Q3 Earnings Per Share Of EUR 0.76
Wednesday, 30 Oct 2019 

Oct 29 (Reuters) - MorphoSys AG ::DGAP-NEWS: MORPHOSYS AG REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS.Q3 NET LOSS -24.2 MILLION EUR VERSUS 30.2 MILLION EUR PROFIT YEAR AGO.Q3 REVENUE 12.5 MILLION EUR.FINANCIAL YEAR 2019 GUIDANCE RE-AFFIRMED: REVENUES EXPECTED TO REACH UPPER END OF EUR65 TO 72 MILLION RANGE.GROUP REVENUES CAME IN AT EUR12.5 MILLION IN Q3 2019 AS COMPARED TO EUR55.0 MILLION IN Q3 OF PREVIOUS YEAR.EARNINGS BEFORE INTEREST AND TAXES (EBIT) IN Q3 2019 TOTALED EUR27.0 MILLION VERSUS EUR30.1 MILLION IN Q3 2018.EARNINGS PER SHARE FOR Q3 2019 WAS EUR 0.76.  Full Article

Morphosys: I-Mab Gets IND Clearance For Trials Of TJ202/MOR202
Monday, 14 Oct 2019 

Oct 14 (Reuters) - MORPHOSYS AG ::I-MAB BIOPHARMA AND MORPHOSYS ANNOUNCE IND CLEARANCE TO INITIATE CLINICAL TRIALS OF TJ202/MOR202 FOR THE TREATMENT OF MULTIPLE MYELOMA IN MAINLAND CHINA.I-MAB WILL NOW BE EXPANDING CLINICAL TRIALS WITH TJ202/MOR202 INTO MAINLAND CHINA.  Full Article

Morphosys And Vivoryon Therapeutics Enter Agreement On Small Molecule Inhibitors Of CD47-SIRP Alpha Signaling In Immuno-Oncology
Tuesday, 9 Jul 2019 

July 8 (Reuters) - Morphosys AG ::DGAP-NEWS: MORPHOSYS AND VIVORYON THERAPEUTICS ENTER AGREEMENT ON SMALL MOLECULE INHIBITORS OF CD47-SIRP ALPHA SIGNALING IN IMMUNO-ONCOLOGY.MORPHOSYS-IN EXCHANGE,CO COMMITTED TO INVESTING UP TO EUR 15 MILLION IN MINORITY STAKE IN VIVORYON AS PART OF A CAPITAL RAISE PLANNED FOR LATER THIS YEAR.MORPHOSYS -CO & VIVORYON THERAPEUTICS ENTERED DEAL UNDER WHICH CO OBTAINED EXCLUSIVE OPTION TO LICENSE VIVORYON'S SMALL MOLECULE QPCTL INHIBITORS IN FIELD OF ONCOLOGY.MORPHOSYS WILL CONDUCT PRECLINICAL VALIDATION EXPERIMENTS ON VIVORYON'S FAMILY OF QPCTL INHIBITORS.MORPHOSYS - IF CO CHOOSES TO EXERCISE OPTION, VIVORYON THERAPEUTICS WILL RECEIVE AN OPTION FEE, AND IS ELIGIBLE FOR MILESTONE PAYMENTS AND ROYALTIES.  Full Article

Morphosys Appoints Jean-Paul Kress As New CEO
Tuesday, 25 Jun 2019 

June 24 (Reuters) - MorphoSys AG ::DGAP-ADHOC: AD HOC: MORPHOSYS APPOINTS JEAN-PAUL KRESS, M.D., AS NEW CHIEF EXECUTIVE OFFICER.APPOINTMENT WILL TAKE EFFECT ON SEPTEMBER 1, 2019.APPOINTMENT NEW CHIEF EXECUTIVE OFFICER WILL TAKE EFFECT ON SEPTEMBER 1, 2019.MORPHOSYS - KRESS WILL SUCCEED DR. SIMON MORONEY, WHO HAD ANNOUNCED HIS DECISION NOT TO RENEW HIS CONTRACT AS A MEMBER OF MORPHOSYS'S MANAGEMENT BOARD.  Full Article

Morphosys Presents Primary Analysis Data From L-Mind Study
Saturday, 22 Jun 2019 

June 22 (Reuters) - MorphoSys AG ::MORPHOSYS PRESENTS PRIMARY ANALYSIS DATA FROM L-MIND STUDY OF TAFASITAMAB (MOR208) IN COMBINATION WITH LENALIDOMIDE IN R/R DLBCL AT ICML 2019.PRIMARY ENDPOINT HAS BEEN MET IN STUDY.L-MIND TREATMENT COMBINATION WAS GENERALLY WELL TOLERATED IN STUDY.ORR WAS 60% (48 OUT OF 80 PATIENTS), AND COMPLETE RESPONSE (CR) RATE WAS 43%.  Full Article

Morphosys's Licensee Janssen Announces Phase 3 Results For Guselkumab
Friday, 14 Jun 2019 

June 14 (Reuters) - MORPHOSYS AG ::MORPHOSYS'S LICENSEE JANSSEN ANNOUNCES TOP-LINE PHASE 3 RESULTS FOR GUSELKUMAB (TREMFYA(R)) IN ADULTS WITH ACTIVE PSORIATIC ARTHRITIS.ACCORDING TO JANSSEN, BOTH STUDIES MET THEIR PRIMARY ENDPOINTS.DATA WILL SERVE AS BASIS OF SUBMISSIONS FOR APPROVAL OF GUSELKUMAB AS A TREATMENT FOR PSORIATIC ARTHRITIS, WHICH ARE ANTICIPATED FOR LATER THIS YEAR.  Full Article

Morphosys Q1 net loss widens to 22.7 million euros
Wednesday, 8 May 2019 

May 7 (Reuters) - MorphoSys AG ::SAYS MOR208: ROLLING SUBMISSION OF L-MIND STUDY DATA TO FDA TO SUPPORT POTENTIAL APPROVAL IN U.S. ON TRACK.SAYS DAVID TREXLER HIRED AS PRESIDENT, MORPHOSYS US INC.; BUILD-UP OF COMMERCIAL CAPABILITIES ONGOING.SAYS MOR208: INTERACTIONS WITH EUROPEAN REGULATORY AUTHORITIES TO EXPLORE USE OF L-MIND AS BASIS FOR A SUBMISSION OF A POTENTIAL MARKETING AUTHORIZATION APPLICATION IN EUROPE ONGOING.SAYS MOR202: PIVOTAL PHASE 2 STUDY IN THIRD LINE AND PHASE 3 STUDY IN SECOND LINE MULTIPLE MYELOMA STARTED BY PARTNER I-MAB IN TAIWAN.SAYS TREMFYA(R): CLINICAL DEVELOPMENT EXPANDED TO INCLUDE ULCERATIVE COLITIS (UC) AND FAMILIAL ADENOMATOUS POLYPOSIS (FAP).SAYS MOR106: START OF PHASE 2 GECKO TRIAL WITH MOR106 AND TOPICAL CORTICOSTEROIDS UNDER AGREEMENT WITH NOVARTIS.SAYS FINANCIAL GUIDANCE FOR 2019 REAFFIRMED.SAYS GROUP REVENUES ROSE TO EUR 13.5 MILLION, COMPARED TO EUR 2.8 MILLION IN Q1 OF 2018.SAYS EARNINGS BEFORE INTEREST AND TAXES (EBIT) AMOUNTED TO EUR -23.6 MILLION IN Q1 OF 2019 (Q1 2018: EUR -19.0 MILLION.SAYS IN Q1 2019, CONSOLIDATED NET LOSS AMOUNTED TO EUR -22.7 MILLION (Q1 2018: EUR -19.5 MILLION). LOSS PER SHARE FOR Q1 OF 2019 WAS EUR -0.72 (Q1 2018: EUR -0.67).  Full Article

Galapagos, MorphoSys Announce Initiation Of Gecko Phase 2 Study
Wednesday, 24 Apr 2019 

April 24 (Reuters) - GALAPAGOS NV ::ANNOUNCED ON TUESDAY INITIATION OF GECKO.GECKO IS A PHASE 2 STUDY TESTING A SUBCUTANEOUS FORMULATION OF MOR106 IN COMBINATION WITH TOPICAL CORTICOSTEROIDS IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS.RECRUITMENT WILL TAKE PLACE IN THE U.S. AND CANADA.STUDY IS INTENDED TO SERVE AS AN IND (INVESTIGATIONAL NEW DRUG) OPENER WITH THE U.S. FDA.  Full Article

Morphosys Says CEO Simon Moroney To Retire
Tuesday, 19 Feb 2019 

Feb 19 (Reuters) - MorphoSys AG ::SIMON MORONEY, CEO AND CO-FOUNDER OF MORPHOSYS, ANNOUNCES HIS INTENTION TO RETIRE.MORONEY WILL STEP DOWN AS CEO ON EXPIRY OF HIS CURRENT CONTRACT ON JUNE 30, 2020, OR WHEN A SUCCESSOR IS APPOINTED, WHICHEVER COMES SOONER.  Full Article

Chief scientist quits at Germany's Morphosys ahead of product launch

FRANKFURT Morphosys' chief scientific officer will quit after 17 years with the group, the latest change at the top of the German biotech firm as it gears up for its first product launch.